Related Experiment Videos
Emerging treatments in multiple sclerosis
1Service de Neurologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Suisse. Myriam.Schluep@chuv.hospvd.ch
European Neurology
|January 1, 1997
Summary
This review covers therapies for multiple sclerosis (MS), focusing on treating relapses and preventing disease progression. It highlights immunomodulatory and immunosuppressive agents like interferon-beta and copolymer 1 for altering MS course.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacology
Background:
- Multiple sclerosis (MS) management involves addressing acute exacerbations, relapse prevention, disability progression, symptom management, and demyelination repair.
- Current therapeutic strategies aim to modify the disease course and improve patient outcomes.
Purpose of the Study:
- To review current and emerging therapies for multiple sclerosis (MS).
- To discuss new insights into treating acute relapses.
- To examine immunomodulatory and immunosuppressive agents for their potential to alter MS progression.
Main Methods:
- Review of existing literature on multiple sclerosis therapies.
- Discussion of recent clinical trial data for immunomodulatory and immunosuppressive agents.
- Focus on specific treatments including interferon-beta (1a and 1b) and copolymer 1.
Main Results:
- Interferon-beta (1a and 1b) and copolymer 1 are established treatments with disease-modifying potential.
- Newer immunosuppressive therapies are being investigated for their efficacy in MS.
- These agents offer potential to impact the natural history of multiple sclerosis.
Conclusions:
- Therapeutic options for MS are expanding, offering new avenues for disease management.
- Immunomodulatory and immunosuppressive treatments are key to altering the course of multiple sclerosis.
- Further research into novel agents is crucial for improving long-term outcomes in MS patients.